Viriom successfully completes clinical safety trial with novel NNRTI, advances to efficacy studies in HIV-infected patients, and to development of HIV microbicide formulation
The Russian Corporation of Nanotechnologies (known as Rusnano) in Moscow, along with a yet-to-be announced co-investor, plans to fund the development of up to 15 potential drug molecules that have unique mechanisms of action, taking them from the preclinical development stage through to Phase 2 clinical trials. "We expect that of the 15 compounds, a few will support the investment," says Andrey Ivaschenko, chairman of ChemRar, the Moscow-based pharmaceutical and biotechnology services company that will provide the first five target molecules. Although the investment is not a huge sum, he notes, a compound can be developed to the Phase 2 clinical stage in Russia for $5-10 million.
Rabochaya St. 2-a, bldg. 1
Khimki, Moscow
141400, Russia
Phone: +7 (495) 995-4944
Fax: +7 (495) 626-9780
www.viriom.com
Definition
What is HIV infection / AIDS?
Infection with HIV (human immunodeficiency virus) can cause AIDS (acquired immunodeficiency syndrome).
HIV proliferates within the human immune system. The virus consists of an outer envelope with docking sites, an inner core containing the genetic information for replication of the virus, and enzymes that regulate this replication. HIV destroys certain white blood cells known as T helper cells or CD4 cells.
The human immune system generally manages to keep HIV in check for years. This means that although the virus is present in the body, the affected person has no symptoms and does not appear to be ill. At this stage the person is said to be HIV-infected, or HIV-positive.
© 2009 F. Hoffmann-La Roche Ltd « Back